Diagnosis Terminology Affects Treatment Decisions

Published Online: Thursday, November 14, 2013
Follow Pharmacy_Times:
According to a recent study published online on August 26, 2013, in JAMA Internal Medicine, women diagnosed with ductal carcinoma in situ (DCIS), a noninvasive breast malignancy, may be more likely to choose surgery over noninvasive options when the condition is described using the word “cancer.”

Recognizing that many women are unable to distinguish between invasive and noninvasive cancers, especially with inconsistent terminology, the researchers investigated whether women’s treatment decisions would be affected by the words used to describe the diagnosis. The study enrolled 394 healthy women and presented them with 3 terms to describe a DCIS diagnosis: noninvasive breast cancer, breast lesion, and abnormal cells. Each term was accompanied by an identical table of risks and 3 treatment options, including surgery, medication, and active surveillance. Women viewed each term separately and were asked to make a treatment decision for each.

The results indicated that women changed their treatment decision when different terms were used to describe DCIS. When the condition was described as “noninvasive breast cancer,” 47% of women said they would want surgery. However, when DCIS was described as a “breast lesion,” 34% wanted surgery, and 31% selected surgery when “abnormal cells” was used.

The authors suggest that many women want nonsurgical treatment when they better understand the risks, but the word “cancer” may scare patients and prevent them from choosing less aggressive treatment.

Related Articles
Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
A vaccine therapy that stimulates the body’s own immune defenses is safe to give to prostate cancer patients early in the disease’s progression, a recent study found.
Researchers have developed a personalized genetic test that can accurately predict the risk for recurrence in prostate cancer patients.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$